Journal
JOURNAL OF ANXIETY DISORDERS
Volume 22, Issue 2, Pages 310-318Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.janxdis.2007.03.001
Keywords
social anxiety disorder; dual-diagnosis; comorbidity; SSRI
Categories
Funding
- NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA013379, K23AA014430, K24AA013314, P50AA010761] Funding Source: NIH RePORTER
- NIAAA NIH HHS [K24 AA013314, K23 AA014430-04, K23 AA014430, R01 AA013379, K23 AA014430-01, K23 AA014430-02, P50 AA010761, K23 AA014430-03] Funding Source: Medline
Ask authors/readers for more resources
Patients with social anxiety disorder who are seen in clinical practice commonly have additional psychiatric comorbidity, including alcohol use disorders. The first line treatment for social anxiety disorder is selective-serotonin-reuptake-inhibitors (SSRIs), such as paroxetine. However, the efficacy of SSRIs has been determined with studies that excluded alcoholics. Forty two subjects with social anxiety and a co-occurring alcohol use disorder participated in a 16-week, double-blind, placebo-controlled clinical trial to determine the efficacy of paroxetine for social anxiety in patients with co-occurring alcohol problems. Paroxetine was superior to placebo in reducing social anxiety, as measured by the Liebowitz Social Anxiety Scale total and subscale scores and additional measures of social anxiety. This study provides the first evidence-based recommendation for the use of an SSRI to treat social anxiety in this patient population. (C) 2007 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available